BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (May 2014)

25 slides from BioSpecifics Technologies's investor presentation, May 14, 2014

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    \ a? Innovators in the development & commercialization of INJECTABLE COLLAGENASE —_—-—~ . OLoG

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements”

  3. Slide 3: Corporate Overview

    Corporate Overview BioSpecifics is a profitable, commercial-stage biopharma company developing injectable collagenase marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU XIAFLEX is now marketed for two indications in the U.S. by strategic partner, Aux

  4. Slide 4: Vast Therapeutic Potential of CCH

    Vast Therapeutic Potential of CCH CCH provides a first-in-class, minimally invasive nonsurgical treatment option for conditions and diseases caused by collagen accumulation where current treatment options are limited BioSpecifics has positive results in 12 indications: Dupuytren’s contracture* Froze

  5. Slide 5: Recent Success Across All Indications

    Recent Success Across All Indications XIAFLEX was approved to be the first and only biologic therapy for the treatment of Peyronie’s disease in men with a palpable plaque and curvature of 30 degrees or greater at the start of therapy BioSpecifics reported data from proprietary pipeline in all three

  6. Slide 6: Approved Indications for XIAFLEX

    Approved Indications for XIAFLEX Preclinical Phase 1 Phase 2 Phase 3 Marketed D Dupuytren’s PDUFA date in 4Q14 for FDA to review sBLA for multi-cord label Contracture Fayre Sobi to file MAA for approval in EU Disease ‘Source: Auxilium Pharmaceuticals, Inc.

  7. Slide 7: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture Formation of a collagen cord in the hand that causes one or more fingers to Definition and contract toward the palm, limiting range of motion of the fingers Key Complications Often results in physical disability, significantly affecting quality of life and daily a

  8. Slide 8: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture Decision Expected in 4Q14 on Label Expansion » PDUFA date is October 20, 2014 for FDA to decide on sBLA, submitted by Auxilium, for XIAFLEX label expansion to allow multiple concurrent injections into same hand Pre-treatment: = sBLA based on positive top-line data

  9. Slide 9: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease Definition & Key Complications XIAFLEX is the First and Only Approved Nonsurgical Therapy Market Opportunity Focus on Patient Access and Market Expansion Source: Auxilium Pharmaceutical, Inc. Excess of inelastic collagen causing penile curvature deformity, which can re

  10. Slide 10: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease Label Consistent with IMPRESS Trials ‘XAFLEX is indicated forthe treatment of adult men with Peyronie's disease with a pwlpable plaque and curvature defer of atleast 30 degrees at the start of therapy. For men with Peyronie's disease, there's good news: the only FDA-ap

  11. Slide 11: XIAFLEX for Peyronie's Disease: Launch Progress

    XIAFLEX for Peyronie’s Disease Launch Progress Focused, disciplined product rollout 5,000-6,500 patients receive invasive treatment for Peyronie’s disease each year (surgery or verapamil injections ) 400 urologists performed about 90% of PD surgeries Initial target is top ~235 of these urologists RE

  12. Slide 12: XIAFLEX for Peyronie's Disease: Launch Progress Cont.

    XIAFLEX for Peyronie’s Disease Launch Progress Cont. - Reimbursement approval by payers (Auxilium Advantage) All eight Medicare beneficiaries confirmed coverage at policy level; 15 major commercial health plans have approved patients for treatment Aetna listed XIAFLEX as 'medically necessary’ in Cli

  13. Slide 13: XIAFLEX Pipeline Programs

    XIAFLEX Pipeline Programs Frozen Top-line data expected in 1Q15 Shoulder *Canine Lipoma “Lista Initiate placebo- trolled trial in 2Q14 Lipoma Initiate placebo-controlled trial in 2Q. Cellulite Top-line data expected in 4Q14 *Uterine Data expected Fibroids *BioSpecifics-managed development program Ch

  14. Slide 14: CCH for Canine and Human Lipomas

    CCH for Canine and Human Lipomas BioSpecifics-Managed Programs Encapsulated deposits of benign fatty tumors often detected as bulges under Definition and the skin that occur in both humans and dogs Key Complications The most common benign tumors found in humans. Can be a serious health problem in do

  15. Slide 15: CCH for Canine Lipomas

    CCH for Canine Lipomas Chien-804 Placebo-Controlled Phase 2 Trial BioSpecifics reported data from placebo-controlled, randomized Phase 2 trial for CCH in dogs with benign subcutaneous lipomas 37 dogs randomized, single injection 1:1 CCH to placebo Primary efficacy endpoint: Relative change in lipoma

  16. Slide 16: CCH for Human Lipomas

    CCH for Human Lipomas Dose Escalation Phase 2 Clinical Trial BioSpecifics reported data from open label, dose escalation Phase 2 trial for humans with benign subcutaneous lipomas 14 patients received single injections of one of four ascending dosage groups ranging from 0.058 mg to 0.44 mg CCH Primar

  17. Slide 17: CCH for Uterine Fibroids

    CCH for Uterine Fibroids Data Expected from Preclinical Studies in 2H14 —) Benign tumors with significant co- eee Definition &: morbidities, which can include pain, = - _ decreased fertility, increased rate of Key Complications miscarriage, heavy menstrual bleeding = and frequent urination. 0 a yh P

  18. Slide 18: CCH for Frozen Shoulder Syndrome

    CCH for Frozen Shoulder Syndrome Top-line Data from Phase 2b Study Expected in 1Q15 Definition and Key Complications Potential to be Only Approved Nonsurgical Therapy Market Opportunity Top-line Data from Phase 2b Study Expected in 1Q15 ‘Source: Auxilium Pharmaceuticals, Inc. Inflammation and thicke

  19. Slide 19: Frozen Shoulder — Statistically Significant CCH Dose Response

    Frozen Shoulder — Statistically Significant CCH Dose Response in Phase 2a Study 60 1 ° 8 P<0.05 Comparison © Forward Flexion 350 i mili [8 Shoulder Abduction a © Extemal Rotation 240 5 Intemal Rotation ry EB 30 a a & 910 H +] e 5 £ vo Mu M a) : ie en i os a R at ‘ git? oat? : gt i Source: Auxilium P

  20. Slide 20: CCH for Cellulite

    CCH for Cellulite Top-line Data from Phase 2a Study Expected in 4Q14 Definition Significant Market Opportunity as First Nonsurgical Therapy Top-line Data from Phase 2a Study Expected in 4Q14 Phase 2a Study Based on Positive Data from Phase 1b Trial Source of data: Auxiium Pharmaceuticals, Inc. Skin

  21. Slide 21: Auxilium Partnership

    Auxilium Partnership BioSpecifics is partnered with Auxilium for the development and commercialization of CCH >$42.6M Received from Auxilium Future Payments Due to BioSpecifics from Auxilium Royalties and Milestone Payment from Second Indication Auxilium Opt-In Rights Milestone Payments from AUXL Pa

  22. Slide 22: Corporate Highlights

    Corporate Highlights Strong Intellectual Property Portfolio Long-term patent protection for injectable collagenase: Dupuytren’s Contracture: XIAFLEX has Orphan Drug protection in U.S. until 2017; Drug product composition patent until 2028 and Biologic Exclusivity until 2022 » Peyronie’s Disease: Aux

  23. Slide 23: Consistently Profitable Annually

    Consistently Profitable Annually 1Q14 Financial Highlights For the quarter For the year ended ended 03/31/14 12/31/13 (unaudited) (unaudited) Cash and equivalents, short term investments s 16,907,795 5 12,591,825 Income Statement Revenues $ 2,761,279 $ 14,467,240 Other income 8,121 26,202 Costs and

  24. Slide 24: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones Steady Momentum in BioSpecifics-Managed Indications Upcoming Milestones *Human 1 Initiate placebo-controlled trial in 2Q14 Lipomas O Complete enrollment in placebo-controlled trial in 4Q14 *Canine QO Chien-804 final study report in 2Q14 Lipomas O Final report triggers

  25. Slide 25: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development is & commercialization of :' “INJECTABLE * COLLAGENASE BioSpecifics May 2014 TECHNOLOGIES CORP

BioSpecifics Technologies — Investor Presentation (May 2014) on 6ix